Common questions about Stafac (FAQ)
Q: Are there any common foods or drinks that interact with Stafac?
Official regulatory documents focus on how Stafac interacts with its vehicle, which is animal feed. The finished medicated feed is restricted from containing certain substances used as pellet-binding agents. Only four specific binding agents—bentonite, Pel-Aid, Agri-Colloid, and Lignosol—are officially permitted for co-administration with the drug.
Q: Does Stafac cause weight gain or weight loss?
The primary purpose of Stafac, according to its official labeling, is to support growth and improve feed efficiency in the approved animal populations. This means the drug helps the animals utilize nutrients more effectively. Regulatory documents do not describe this intended positive effect on growth as a side effect or adverse reaction.
Q: What is the typical timeframe for a treatment course with Stafac?
The required duration of use is defined in the regulatory administration guidelines. For example, in swine, the recommended treatment timeframe is for a period of two weeks, followed by a control dose. For broiler chickens, Stafac is typically administered continuously as the animal’s only feed ration, which may continue for the entire approved production period.
Q: What are the most commonly reported serious side effects of Stafac?
Official regulatory documentation for this product, which is a Veterinary Feed Directive (VFD) drug, is different from human drug labeling. The documents do not include a conventional list of adverse reactions (side effects) categorized by frequency or body system for the treated animals. The safety profile is defined primarily through mandatory regulatory restrictions and oversight.
Q: Is the brand name Stafac the same as the generic drug?
The product name Stafac is the brand name used for the active ingredient it contains, which is Virginiamycin. Virginiamycin is the non-proprietary chemical name, which is often considered the generic name for the compound.
Q: What are the typical expected outcomes described in the research for Stafac?
Regulatory documents and supporting research detail several expected outcomes. These include improved feed efficiency and the prevention of specific bacterial diseases, such as necrotic enteritis in broiler chickens. Studies have also been conducted to measure changes in certain disease-related scores in participants.
Q: Does Stafac carry a risk of allergic reaction?
While the official documentation does not list allergic reactions for the animals treated with the feed, safety documents for handlers of the raw premix powder advise caution. These documents recommend avoiding inhalation and direct skin contact, noting that direct contact may lead to irritation or hypersensitivity responses in the human handler.
Q: Is Stafac available in different strengths or forms?
Stafac is formulated as a Medicated Feed Premix Powder known as a Type A Medicated Article. While the final delivery form is always in the feed, the premix is available in different concentrated versions, such as Stafac 20, 50, or 500, which are mixed into the animal feed at different specified concentrations.
Q: What are the circumstances under which official bodies recommend stopping Stafac?
Use of Stafac must be stopped immediately if the animal reaches a state that is contraindicated (prohibited) for the drug. This includes if breeding swine exceed 120 pounds in weight, or if the authorizing document, the Veterinary Feed Directive (VFD), expires or is no longer valid.
Q: What does 'contraindicated' mean in the context of Stafac?
In the regulatory context of Stafac, the term contraindicated specifies a condition or population where the drug must not be used due to safety concerns. This exclusion is absolute for specific groups, including humans, laying chickens, and breeding swine over 120 pounds.
Q: Does Stafac have a 'Black Box' warning from the FDA, and what does it mean?
Stafac does not carry an FDA Black Box Warning, which is typically reserved for very serious safety concerns with human drugs. The primary regulatory caution is its designation as a Veterinary Feed Directive (VFD) drug, which restricts its use to a licensed veterinarian’s order under Federal law.
Q: What are the documented signs of an accidental overdose of Stafac?
Safety documents for the raw active ingredient indicate that the accidental ingestion of large quantities may result in signs such as constipation or diarrhea. Any animal that has ingested more than the specified amount would require an assessment by a licensed veterinarian.
Q: Is Stafac considered a controlled substance?
No, official labeling confirms that Stafac has a DEA Schedule of None, meaning it is not classified under drug control law. However, its use is strictly regulated by Federal law as a Veterinary Feed Directive (VFD) Drug, which requires veterinary oversight.
Q: Is Stafac effective against all the types of issues it is used for?
Stafac is approved for use against specific issues, such as preventing necrotic enteritis caused by the bacterium Clostridium perfringens in broilers. The drug's efficacy is specifically limited to the treatment of conditions caused by organisms that are susceptible to virginiamycin.
Q: Are there any long-term health risks officially linked to taking Stafac?
For broiler chickens, official safety classification indicates that when the drug is used compliantly, a zero withdrawal period is required before the animals can enter the food supply. This key safety feature ensures that there are no illegal drug residues in the final food product, which is a major regulatory consideration for human health protection.
